Functionally Active HIV-Specific T Cells that Target Gag and Nef Can Be Expanded from Virus-Naïve Donors and Target a Range of Viral Epitopes: Implications for a Cure Strategy after Allogeneic Hematopoietic Stem Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 22, Issue 3, 2016, Pages 536-541

  Patel, Shabnum ^a,b   Lam, Sharon ^a   Cruz, Conrad Russell ^a   Wright, Kaylor ^a   Cochran, Christina ^b   Ambinder, Richard F ^c   Bollard, Catherine M ^a  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adoptive immunotherapy; Human immunodeficiency virus

Indexed keywords

EPITOPE; GAG PROTEIN; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; NEF PROTEIN; NEF PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; VIRUS ANTIGEN;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIGEN SPECIFICITY; ARTICLE; CELL EXPANSION; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; EPITOPE MAPPING; EX VIVO STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IN VITRO STUDY; INFECTION PREVENTION; NONHUMAN; PATHOGEN CLEARANCE; PERIPHERAL BLOOD MONONUCLEAR CELL; REPRODUCIBILITY; VIRUS INHIBITION; VIRUS RESISTANCE; ALLOGRAFT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; LYMPHOCYTE TRANSFUSION;

ALLOGRAFTS; ANTIGENS, VIRAL; EPITOPES, T-LYMPHOCYTE; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIV-1; LYMPHOCYTE TRANSFUSION; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 85009444421     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2015.12.007     Document Type: Article

References (18)

1. 1 Hutter, G., Nowak, D., Mossner, M., et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 360 (2009), 692–698.
2. 2 Smiley, S.T., Singh, A., Read, S.W., et al. Progress toward curing HIV infections with hematopoietic stem cell transplantation. Clin Infect Dis 60 (2015), 292–297.
3. 3 Galvani, A.P., Novembre, J., The evolutionary history of the CCR5-Delta32 HIV-resistance mutation. Microbes Infect 7 (2005), 302–309.
4. 4 Durand, C.M., Ambinder, R.F., Hematopoietic stem cell transplantation in HIV-1-infected individuals: clinical challenges and the potential for viral eradication. Curr Opin Oncol 25 (2013), 180–186.
5. 5 Henrich, T.J., Hanhauser, E., Marty, F.M., et al. Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases. Ann Intern Med 161 (2014), 319–327.
6. 6 Gerdemann, U., Katari, U.L., Papadopoulou, A., et al. Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. Mol Ther 21 (2013), 2113–2121.
7. 7 Heslop, H.E., Slobod, K.S., Pule, M.A., et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 115 (2010), 925–935.
8. 8 Hanley, P.J., Brenner, M.K., Leen, A.M., et al. Evaluating multivirus-specific T cells from both cord blood and bone marrow transplant donors: a phase 1 perspective. Cytotherapy 16 (2014), S7–S8.
9. 9 Hanley, P.J., Cruz, C.R., Savoldo, B., et al. Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood 114 (2009), 1958–1967.
10. 10 Hanley, P.J., Melenhorst, J.J., Nikiforow, S., et al. CMV-specific T cells generated from naive T cells recognize atypical epitopes and may be protective in vivo. Sci Transl Med, 7, 2015, 285ra263.
11. 11 Leen, A.M., Myers, G.D., Sili, U., et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 12 (2006), 1160–1166.
12. 12 Los Alamos National Laboratory. HIV Databases. Available at: http://www.hiv.lanl.gov/content/index. Accessed November 25, 2015.
13. 13 Leen, A.M., Bollard, C.M., Mendizabal, A.M., et al. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood 121 (2013), 5113–5123.
14. 14 Hanley, P.J., Cruz, C.R., Shpall, E.J., Bollard, C.M., Improving clinical outcomes using adoptively transferred immune cells from umbilical cord blood. Cytotherapy 12 (2010), 713–720.
15. 15 Lund, T.C., Boitano, A.E., Delaney, C.S., et al. Advances in umbilical cord blood manipulation-from niche to bedside. Nat Rev Clin Oncol 12 (2015), 163–174.
16. 16 Gerdemann, U., Katari, U., Christin, A.S., et al. Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma. Mol Ther 19 (2011), 2258–2268.
17. 17 Micklethwaite, K.P., Savoldo, B., Hanley, P.J., et al. Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation. Blood 115 (2010), 2695–2703.
18. 18 Cannon, P., June, C., Chemokine receptor 5 knockout strategies. Curr Opin HIV AIDS 6 (2011), 74–79.